logo
Women likely ruled in Stone Age China, DNA analysis of 4,500-year-old skeletons reveals

Women likely ruled in Stone Age China, DNA analysis of 4,500-year-old skeletons reveals

Yahoo21-06-2025
When you buy through links on our articles, Future and its syndication partners may earn a commission.
Women headed communities in eastern China about 4,500 years ago, a DNA analysis reveals.
While analyzing the ancient DNA of skeletons buried in Stone Age cemeteries in China, archaeologists discovered that the society was organized in an extremely rare way: Everyone belonged to one of two clans headed by women, and people were buried in their maternal clans for at least 10 generations.
At the archaeological site of Fujia in eastern China, researchers discovered two cemeteries roughly 330 feet (100 meters) apart flanking an ancient residential area. More than 500 burials were excavated and radiocarbon-dated to between 2750 and 2500 B.C.
In a study published June 4 in the journal Nature, an international team of researchers detailed their analysis of the DNA of 60 skeletons discovered at Fujia — 14 from the north cemetery and 46 from the south cemetery.
All 14 people from the north cemetery shared the same type of mitochondrial DNA (mtDNA), which is transmitted only from mother to child. This suggests that all of the people had the same maternal lineage, the researchers wrote in the study.
In the south cemetery, the researchers identified a different mitochondrial DNA lineage that was shared by 44 of the 46 people they tested. And when the researchers analyzed the Y chromosomes from the male skeletons, they found a high degree of diversity. Together, those findings suggest that the fathers of those buried in the cemeteries came from different lineages while the mothers were related.
"By integrating mtDNA and Y-chromosome analyses, we provide evidence that most individuals at Fujia, irrespective of their sex, were buried according to their maternal lineage," the researchers wrote in the study. In particular, both teenage and adult males were buried exclusively in their maternal clans, which "aligns with the common norms of a matrilineal society," according to the study.
Such findings of ancient societies organized along maternal lines are rare. Only three other studies have used DNA analysis to identify matrilineal communities: Chaco Canyon in New Mexico, Celtic elites in southern Germany, and the Durotriges in Iron Age Britain. Similar practices, however, have been found in contemporary Southeast Asian matrilineal societies.
Related: 'Overkill' injuries on Bronze Age skeletons reveal fierce feuding in ancient China
Deeper analysis revealed high rates of "consanguinity" — marrying a blood relative — over the span of 10 generations. While many people likely married their second or third cousins, four individuals showed signs of mating with first cousins or closer relatives.
While such consanguinity may not be the preferred marriage pattern, it inevitably occurs when you have small, closed-off societies, the researchers wrote.
RELATED STORIES
—Complete Bronze Age town with elite tombs discovered in northern China
—Lavish 2,200-year-old tomb unearthed in China may be that of ancient king
—2,200-year-old grave in China contains 'Red Princess of the Silk Road' whose teeth were painted with a toxic substance
This "unique social organization" has not been found previously in Stone Age East Asian populations, according to the researchers.
"It is exciting to find a matrilineal society in Neolithic China," Yu Dong, an archaeologist at Shandong University who was not involved in the study, said in a statement.
The Fujia study provides key insights into the social and environmental conditions during the transition from smaller to more complex societies, the researchers wrote. Future DNA and archaeological research should help clarify matrilineal social organization in early human societies, they added.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

More Data Cement COVID's Impact on Patients With Cancer
More Data Cement COVID's Impact on Patients With Cancer

Medscape

time9 minutes ago

  • Medscape

More Data Cement COVID's Impact on Patients With Cancer

TOPLINE: New data confirm the impact COVID infection can have on patients with cancer and identified several risk factors associated with hospitalization and death. Receipt of chemotherapy as well as a baseline history of stroke, atrial fibrillation, or pulmonary embolism were each associated with nearly double the risk for COVID-related hospitalization. Prior vaccination halved this risk. Older age and earlier hospitalization were associated with a greater risk for death. METHODOLOGY: Patients undergoing active cancer treatment are at increased risk for severe COVID-19 due to immunosuppression, but risk factors for hospitalization and death are not well-defined. Researchers conducted a prospective cohort study involving 1572 patients with cancer (median age, 60 years; 53.4% women), enrolled within 14 days of a positive SARS-CoV-2 test; participants had received active treatment for cancer within 6 weeks before testing or had undergone prior stem cell transplant or CAR T-cell therapy. Patient screening and enrollment took place between May 2020 and February 2022. Treatments included chemotherapy (34.3%), targeted therapy (27.7%), and immunotherapy (10.6%). Breast (23.6%) and lung (13.9%) cancers were the most common cancer types. Overall, 64% of participants had metastatic disease, and at enrollment, 64% had not received a COVID vaccine. Study outcomes were COVID-related hospitalization or death. Risk factors for hospitalization and for death among hospitalized patients were evaluated separately. TAKEAWAY: At 90 days after an initial positive test, COVID-related mortality was 3% and remained stable at subsequent follow-ups. The highest incidence occurred in patients with lymphoma, followed by those with acute leukemia or lung cancer; the lowest incidence occurred in those with other types of solid tumors and blood cancers. Hospitalization for COVID-19 occurred in 18.4% of patients within 90 days of enrollment. The risk for hospitalization was elevated among patients who received chemotherapy (hazard ratio [HR], 1.97) and those with a history of stroke, atrial fibrillation, and pulmonary embolism (HR, 1.78). Vaccination prior to infection reduced the risk for hospitalization by nearly half (HR, 0.52). Hospitalization for COVID-19 within 30 days of infection was associated with an increased risk for death (HR, 14.6). Among patients hospitalized for COVID within 30 days, age 65 years or older was the only significant predictor of COVID-specific death (HR, 3.49). Over the 2-year follow-up, there were 1739 disruptions to cancer treatment; 50.7% of these were attributed to COVID-19, and most occurred within 30 days of a positive test. IN PRACTICE: 'The data from this prospective cohort study confirm and expand previous retrospective case series that have found factors, including hematologic cancers, chemotherapy receipt, and lung cancer, as associated with COVID-19 severity,' the authors of the study wrote, noting that the results 'showed that COVID-19 had a significant impact on patients with cancer, including hospitalization, treatment disruptions, and death.' SOURCE: This study, led by Brian I. Rini, MD, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, was published online in JAMA Oncology. LIMITATIONS: Information on specific strains was not available. This study lacked a control group of patients without COVID-19, which limited causal inference. Additionally, as participants were enrolled through the National Cancer Institute trial networks, generalizability to a broader population could be limited. DISCLOSURES: This study was funded in part by the Coronavirus Aid, Relief, and Economic Security Act and the National Cancer Institute National Clinical Trials Network, Experimental Therapeutics Clinical Trials Network, and Community Oncology Research Program grants via the U10 funding mechanism. Several authors declared receiving grants and/or personal fees and having other ties with various sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

A New COVID Variant Is Here, And It's More Transmissible — Here Are The Signs And Symptoms
A New COVID Variant Is Here, And It's More Transmissible — Here Are The Signs And Symptoms

Yahoo

time28 minutes ago

  • Yahoo

A New COVID Variant Is Here, And It's More Transmissible — Here Are The Signs And Symptoms

A new COVID variant known as NB.1.8.1 has made landfall in the United States. As of late May, the variant, which was first detected in China this past January, accounted for 10% of the SARS-CoV-2 sequences tested from around the world, recent surveillance data found. That's a significant jump from 2.5% four weeks prior. A Centers for Disease Control and Prevention (CDC) spokesperson told HuffPost that the agency is in regular contact with international partners about the activity of NB.1.8.1. Up until late May, only 20 NB.1.8.1 sequences had been identified in the U.S. — that's below the threshold needed for a variant to appear on the agency's COVID dashboard. (As soon as its prevalence increases, NB.1.8.1 will pop up on the tracker, the spokesperson added.) It's nerve-wracking to hear that a new variant is making the rounds, but infectious disease specialists say there are no glaring differences between the symptoms of NB.1.8.1 and those caused by other versions of SARS-CoV-2. 'Currently it appears that NB.1.8.1 would have similar symptoms to other COVID variants that have recently been circulating,' Dr. Zachary Hoy, a pediatric infectious disease specialist with Pediatrix Medical Group in Nashville, Tennessee, told HuffPost. Here's what to know about the newest COVID variant that's gaining traction around the world. NB.1.8.1's mutations likely make it more transmissible. Compared to the currently dominant variant in the U.S. (LP.8.1), NB.1.8.1 has a handful of new mutations on the spike protein that may enhance its ability to bind to our cells, according to the World Health Organization (WHO). The agency suspects these mutations will increase the virus's transmissibility and, potentially, diminish the effectiveness of neutralizing antibodies that prevent pathogens from latching to our cells. In other words, the variant may be skilled at dodging some of our immune defenses, research suggests. Here are the signs and symptoms doctors are seeing with NB.1.8.1. According to Dr. Amesh Adalja, an infectious diseases expert and senior scholar at the Johns Hopkins University Center for Health Security, NB.1.8.1's symptoms are pretty much the same as those seen with other SARS-CoV-2 variants. Two of COVID's hallmark symptoms are a mild but persistent dry cough and nasal congestion, Hoy said. Many people who come down with COVID are also hit with fatigue and tiredness. 'An infected person can still make it through the day, but they are resting more and feel more tired throughout the day,' Hoy said. Other common symptoms include a fever, chills, a sore throat and muscle aches. 'Some have described recent variants as less intense symptoms as compared to wintertime influenza viruses, but both can have severe symptoms,' Hoy said. There's no evidence suggesting the variant causes more severe disease or an uptick in hospitalizations or deaths, the WHO states. The only noticeable aspect, as of now, is that it's rising in prevalence, Adalja said. How effective are the vaccines against NB.1.8.1? It's too early to know exactly how effective the shots are — as the research on NB.1.8.1 is limited since it's so new — but scientists expect the shots to hold up well. NB.1.8.1 broke off from the Omicron JN.1 lineage, which the 2024-2025 vaccines target. 'The ability of the vaccines to prevent severe illness is intact though protection versus infection is limited and transient,' Adalja said. Anyone who is at risk of severe disease should stay up-to-date with the shots. 'Those in older populations or with underlying immune disorders or on immune-decreasing medications would benefit more from vaccination or those with increased exposure such as healthcare workers,' Hoy added. So if you have a condition that puts you at risk, it's worth getting vaccinated if it's been more than six months since your last vaccine or bout of COVID, Adalja advises. He also added that those who are low-risk likely do not need to go out and get another shot. Know when to treat NB.1.8.1 at home and when to go visit a doctor. Most people will be able to recover at home by resting and staying hydrated. While you're sick, acetaminophen and ibuprofen can help alleviate muscle aches and fevers, Hoy said. And, in most cases, symptoms should clear up within a week. For those who are at risk for severe disease, including older adults and people who are immune-compromised, it's worth contacting a physician as they can prescribe antivirals — Paxlovid and Molnupiravir — that can significantly lower the risk of severe complications and death. As was the case with previous variants, these antivirals work best when started within five days of symptom onset. As for when you should go to an urgent care or emergency room? When you have chest pain, have a hard time waking up or staying awake, or feel confused and disoriented, the CDC advises. Hoy says the most concerning symptom he warns patients about is difficulty breathing. 'If you have COVID or COVID-like illness and have worsening trouble breathing or chest pain, you should be evaluated at your doctor's office, urgent care or the ER,' he said. Related... RFK Jr. Says COVID Shot Will No Longer Be Advised For Healthy Kids, Pregnant Women COVID Cases Are Rising This Summer, But Not All The Data Shows It — Here's Why People Are Reporting A Frightening COVID Symptom Right Now — Here's What To Know

HKSTP Takes Nine Game-Changing AI Tech Ventures to WAIC 2025 to Advance China's AI Plus Vision in Transforming Business and Industry
HKSTP Takes Nine Game-Changing AI Tech Ventures to WAIC 2025 to Advance China's AI Plus Vision in Transforming Business and Industry

Associated Press

time5 hours ago

  • Associated Press

HKSTP Takes Nine Game-Changing AI Tech Ventures to WAIC 2025 to Advance China's AI Plus Vision in Transforming Business and Industry

HONG KONG SAR / SHANGHAI, CHINA - Media OutReach Newswire - 27 July 2025 - Hong Kong Science and Technology Parks Corporation (HKSTP) is embarking on a mission to advance China's AI Plus vision with nine Hong Kong AI park companies at the World AI Conference & High-Level Meeting on Global AI Governance (WAIC) 2025, taking place from July 26-29 in Shanghai, China. In collaboration with the Hong Kong Trade Development Council and Cyberport, HKSTP is leveraging Hong Kong's growing global AI innovation hub status to advance the China's strategic AI initiative and applying AI and big data to transform old and new industry sectors to boost a new era of growth. HKSTP is embarking on a mission to advance China's AI Plus vision with nine Hong Kong AI park companies at the WAIC 2025. Mr. Eric Or, Acting Chief Corporate Development Officer, HKSTP, said: 'Hong Kong is a crucible for world-class AI innovation and our unique HKSTP ecosystem provides an ideal platform to empower AI tech firms with global fluency and pave the way for global expansion. By taking local tech companies on a global growth journey and attracting more international startups to land Hong Kong and integrating into the Mainland China or even the Asia markets means a growing critical mass of world-class AI innovators is created. This influx of global talent and technology will accelerate the country's high-tech industry and economic development, further fueling the national drive for new quality productive forces.' The nine park enterprises participating in the Hong Kong Pavilion cover technologies in life and health tech, fintech, entertainment, aerospace tech, digital education and more, highlights included: In addition to the showcase of tech firms, HKSTP also hosted a provoking panel discussion at WAIC 2025, exploring the theme of: 'From Hong Kong to global impact: Shaping the future with AI and New Quality Productive Forces for Cross-industry Growth', moderated by Ms Pheona Kan, Director of Business Development at HKSTP with the fellow scientists and experts from the field. The discussion highlighted how Hong Kong has a unique role in global AI development by uniting international talent and technology behind the city's AI vision which also aligns with China's vision to transform industry through quality productive forces. As the largest I&T ecosystem in Hong Kong, HKSTP is home to over 500 AI startups, including home-grown unicorns that are shaping the future of artificial intelligence. In alignment with Hong Kong's bold vision for technological leadership, the HKSTP San Tin Technopole Campus—a 20-hectare site within the soon-to-be-built San Tin Technopole—will serve as a critical catalyst for the city's next wave of innovation. Strategically located in the heart of the Northern Metropolis, the Campus is poised to become a flagship landmark for AI+ and beyond, aiming to promote its widespread development and application across sectors. This year, WAIC 2025, themed 'Global Solidarity in the AI Era,' will bring together top scientists, global leaders, entrepreneurs, policymakers, and innovators in the AI ecosystem. KSTP's participation at WAIC 2025 is a testament to Hong Kong's role as a bridge between Chinese and global innovators, fostering collaboration and exchange of ideas, technologies, and governance philosophies. Appendix 1: List of park companies at Hong Kong Tech Pavilion Hashtag: #HKSTP The issuer is solely responsible for the content of this announcement. About Hong Kong Science and Technology Parks Corporation Hong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 13 unicorns, more than 15,000 research professionals and over 2,300 technology companies from 26 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc. Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined. Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more. Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in establishing I&T as a pillar of growth for Hong Kong. More information about HKSTP is available at

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store